New England Journal of Medicine · 2015 · 28 citations · 2 references
PharmacyCardiologyPharmaceutical PolicyCardiovascular PharmacotherapyHealth InsuranceInsurance EconomicsHealth Insurance MarketsHealthcare PricingInsurance PricingLipid-lowering TherapyMedication Coverage PolicySpecialty Drug CoverageHealth Insurance PremiumsHyperlipidemia TreatmentInsurance Coverage For MedicationsInsurance Coverage Of MedicinesPcsk9 Inhibitor TherapyPcsk9 InhibitorsPharmaceutical Pricing StrategySpecialty Drug Pricing
Interview with Dr. Kevin Schulman on the recent approval of two PCSK9 inhibitors and what their prices could mean for insurance premiums. (09:12)Download The approval of PCSK9 inhibitors with broad indications sets the practice of cardiology on a collision course with specialty pharmaceutical pricing models that were previously reserved for drugs that benefited relatively limited patient populations.
2